Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 14 Jan 2019 Planned End Date changed from 1 Aug 2023 to 31 Aug 2023.
- 14 Jan 2019 Planned primary completion date changed from 1 Feb 2021 to 28 Feb 2021.
- 06 Dec 2018 New trial record